focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.00
Bid: 33.00
Ask: 37.00
Change: 0.00 (0.00%)
Spread: 4.00 (12.121%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 35.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Capita and Custodian REIT agree disposals

Fri, 30th Jul 2021 19:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Capita PLC - London-headquartered outsourcer - Completes sale of Axelos Ltd, its joint venture with the UK government, to PeopleCert International Ltd. Deal values Axelos at GBP380.0 million on a cash-free, debt-free basis. Capita owns 51% of the business, and will receive proceeds of GBP172.5 million from the sale plus an GBP11.1 million dividend, for a total of GBP183.6 million. The UK government, which owns the remaining 49% of Axelos, also will sell its stake.

----------

Custodian REIT PLC - Leicester, England-based real estate investment trust - Sells portfolio of properties for GBP23.4 million. The portfolio comprises five industrial sites in Gateshead, Stockton-on-Tees, Warrington, Stone and Christchurch with a current passing rent of GBP1.4 million. The properties within the portfolio were acquired either in the seed portfolio at IPO or within subsequent portfolio acquisitions. Agreed sale price is 21% above March 31 valuation. Richard Shepherd-Cross, managing director of Custodian Capital, the company's external fund manager, says: "Investment demand and pricing for industrial assets are both at record levels, so we believe now is the best time to sell to capitalise on the current, favourable market dynamics to secure a significant profit."

----------

Sareum Holdings PLC - Cambridge, England-based molecule drug discovery firm - Notes the US Patent & Trademark Office backs a patent associated with Sareum's SDC-1802 TYK2/JAK1 kinase inhibitor programme. SDC-1802 is a cancer treatment.

----------

Augean PLC - Walton, England-based hazardous waste treatment and disposal company - Accepts 280 pence per share offer from Morgan Stanley Infrastructure Inc. Company closed at 295p in London on Friday, but is 36% premium to company's daily volume weighted average share price of 220.8p. Executive Chair Jim Meredith says: "The board of Augean believes that MSIP is well-respected as a long-term investor in the infrastructure sector and will be able to support Augean's strategy of providing the highest level of customer service and safe operations in niche and highly regulated hazardous waste markets which should allow the business to develop its services to an increasing breadth of customers while offering commensurate opportunities for our employees." Says offer provides attractive value to Augean shareholders.

----------

Premier Miton Group PLC - London-based asset manager - Ends June 30 with net asset value per share of 177.59 pence, up 2.4% from 173.48p at December 31. Declares dividend of 4.45p, down from 5.60p year before. NAV total return in first half 4.2%, down from FTSE Global Core Infrastructure 50/50 Total Return Index advancing 6.3%. "Investment activity was lower than recent levels, and unlike 2020, we have not felt the need to carry out equity market hedging activities. The renewables and clean energy sectors were weak in the first half of 2021; however, despite this, PMGR managed to generate a positive return. This was partly due to some very strong performances in a small number of investments in China, which more than offset modest losses elsewhere," Fund manager James Smith says.

----------

Thor Explorations Ltd - Vancouver, Canada-based gold exploration and development company - Starts first gold pour from its Segilola gold mine located in Osun State, Nigeria. The pour took place July 30. The process plant ramp up will continue over the next six weeks with commercial production targeted for September 2021. At commercial production, the plant will run at a processing rate of 715,000 tonnes per annum, targeting about 85,000 ounces of gold per annum. Chief Executive Segun Lawson says first pour is "significant achievement".

----------

Aberdeen New Thai Investment Trust PLC - investment firm - Proposes voluntary winding-up, a partial cash exit opportunity and a rollover into Aberdeen Emerging Markets Investment Co Ltd. Moves will give it exposure to investing directly in Chinese equities and "highly successful" Aberdeen Standard Investments equities team. At June 30, AEMC has gross assets of GBP388 million, and will change its investment policy to one of investing directly in Chinese equities.

----------

Sutton Harbour Group PLC - Plymouth-based harbour operator - Gets valid offers for 13.1 million shares in open offer and a further 899,830 under an excess application facility, raising GBP3.5 million.

----------

Alien Metals Ltd - London-based mineral exploration and development company - Exclusivity agreement with owner of the Elizabeth Hill silver tailings project, located on the Elizabeth Hill silver project site, has come to an end. Chief Executive Bill Good says: "With a number of key project developments and priority technical work in the pipeline, we have decided to suspend our current work and review of the Project. We still see potential in the silver tailings, and may revisit the Project in due course when other projects will allow for this."

----------

Nostrum Oil & Gas PLC - oil & gas exploration and production company operating in Kazakhstan - Expects first half revenue to be over USD92 million, flat year on year. Average daily production after treatment for first half totalled 18,107 boepd with average daily sales volumes of 16,249 boepd. "The production decline means that we do not make condensate sales each month because we have insufficient volumes to form a cargo. Condensate inventory at June 30 amounted to approximately 220,000 barrels," company explains. Chief Executive Arfan Khan says: "We continue to engage with parties interested in using the spare capacity in our gas processing facilities to process their gas as well as the local and national government departments who will be essential to such projects."

----------

TechFinancials Inc - fintech software provider - Improves to pretax profit of USD897,000 in 2020 from USD6.2 million loss in 2019. Revenue drops to USD1.3 million from USD3.4 million. Research & Development expenses drops to USD512,000 from USD2.2 million, and administrative expenses falls to USD654,000 from USD2.6 million.

----------

Dispersion Holdings PLC - investor in decentralised finance, which uses blockchain and cryptocurrencies to remove financial intermediaries from transactions - Pretax profit in six months to April 30 was GBP145,167, on GBP945,000 fair value adjustment. Administrative expenses GBP799,854. Completes IPO on London's AQSE Growth Market on April 30 with market cap of GBP18.3 million. Chief Executive Michael Edwards says: "Our successful flotation on the AQSE Growth Market was Dispersion's most important milestone during the first half. It has provided us with the capital and credibility to be an early investor in the rapidly growing global market of decentralised finance as well as to take a ring-side seat at London's world-class and hugely promising fintech sector, which is spawning many new disruptive businesses with great long term potential." Says made "flying start" with six investments.

----------

Safestay PLC - London-based hostels operator - Pretax loss in 2020 widens to GBP10.1 million from GBP635,000 in 2019. Revenue drops sharply to GBP4.8 million from GBP18.4 million. Administrative expenses slips to GBP11.5 million from GBP13.0 million. Chair Larry Lipman says: "2020 was an extraordinary year which brought the global travel industry to a near standstill. For Safestay, our hostels closed for more than seven months which is clearly reflected in our trading performance. Like others, our focus switched to first protecting the business and then securing the capital to enable the business to re-emerge strongly. In this we have been successful, through first substantially reducing our cost base, taking advantage of government grants and renegotiating rental terms with our landlords. As a result, our monthly fixed costs reduced from GBP1.0 million to GBP350,000. More recently, we completed the sale of two assets to raise GBP16.8 million giving us sufficient capital to compete strongly for when the market recovers, and new opportunities arise."

----------

KRM22 PLC - risk management company - Signs contract extension with an existing Risk Cockpit customer. Signed a three-year contract extension with an unnamed tier one customer, with annual recurring revenue of GBP400,000 per year, an increase in existing ARR of GBP150,000 per year. In addition to the immediate increase in ARR, the contract includes an option to increase ARR further by up to GBP200,000 by March 2022. Executive Chair Keith Todd says: "I'm pleased that we can announce this contract signature. As stated in the trading update, the precise timing of contract signature is uncertain however we expect further contract signatures in the near future. The contract extension for a further three years is endorsement of our Risk Cockpit product applied to operational risk management."

----------

Apollon Formularies PLC - London-based medical cannabis pharmaceutical firm - Extends existing right to purchase option to acquire US-based beverage company CBev Ventures Inc which expires on July 30, for a further 90 days ending October 28. The company intends to use the extended option period to conduct small-scale commercial trials on CBev's product range prior to any potential exercise of the RPU. CBev develops, markets and distributes functional and craft proprietary non-alcoholic beverages in the legal CBD.

----------

Thalassa Holdings Ltd - invests in real estate, fintech and robotics - Enters into non-legally binding heads of terms between Anemoi International Ltd and one of its investee companies, id4 AG for the proposed acquisition of the entire issued share capital of id4 by Anemoi. "The board carefully considered id4's stage of development, funding needs and potential benefits of becoming part of a listed entity with id4's founders and senior management team. Following these discussions, it was agreed that the opportunity offered by Anemoi should be taken forward and accordingly the Heads of Terms were entered into," company says.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
5 May 2023 15:53

Sareum gets approval for phase one psoriasis studies in Australia

(Sharecast News) - Biotechnology developer Sareum Holdings announced on Friday that it has been granted approval by Australia's Therapeutic Goods Administration (TGA) to conduct phase one clinical studies on SDC-1801.

Read more
5 May 2023 11:26

Sareum receives Australian approval for psoriasis drug clinical trial

Alliance News) - Sareum Holdings PLC on Friday said its application to start a phase 1 clinical trial in Australia of its lead product, psoriasis drug SDC-1801, has been approved.

Read more
5 May 2023 11:11

AIM WINNERS & LOSERS: Aptamer says struggling to convert pipeline

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
22 Mar 2023 11:47

Sareum Holdings interim loss widens as touts psoriasis candidate drug

(Alliance News) - Sareum Holdings PLC on Wednesday reported an increased half-year loss for the six months to December 31, as it continued to work on its psorasis candidate drug SDC-1801.

Read more
17 Mar 2023 18:06

IN BRIEF: Sareum makes trial application for SDC-1801 in Australia

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune disease and cancer - On Wednesday, says it has begun an application to perform phase one clinical studies on SDC-1801 in Australia under the clinical trial notification scheme.

Read more
15 Mar 2023 15:43

UK earnings, trading statements calendar - next 7 days

Thursday 16 March 
Capital LtdFull Year Results
Centamin PLCFull Year Results
Deliveroo PLCFull Year Results
DFS Furniture PLCHalf Year Results
Empiric Student Property PLCFull Year Results
Eurocell PLCFull Year Results
FW ThorpeHalf Year Results (TBC)
Gelion PLCHalf Year Results
Gem Diamonds LtdFull Year Results
Gym Group PLCFull Year Results
Halma PLCTrading Statement
Helios Towers PLCFull Year Results
Hostmore PLCFull Year Results
Investec PLC and LtdTrading Statement
National World PLCFull Year Results
OSB Group PLCFull Year Results
PensionBee Group PLCFull Year Results
Polymetal International PLCfull Year Results
PYX Resources LtdFull Year Results
Rentokil Initial PLCFull Year Results
Restore PLCFull Year Results
Savills PLCFull Year Results
TI Fluid Systems PLCFull Year Results
WAG Payment Solutions PLCFull Year Results
Friday 17 March 
no events scheduled 
Monday 20 March 
Jubilee Metals Group PLCHalf Year Results
Tuesday 21 March 
Alliance Pharma PLCFull Year Results
Aptitude Software Group PLCFull Year Results
Boku IncFull Year Results
Diversified Energy Co PLCFull Year Results
Ergomed PLCFull Year Results
Fintel PLCFull Year Results
Gamma Communications PLCFull Year Results
Henry Boot PLCFull Year Results
Kape Technologies PLCFull Year Results
Kingfisher PLCFull Year Results
Luceco PLCFull Year Results
MP Evans Group PLCFull Year Results
Ocado Group PLCTrading Statement
Oxford Nanopore Technologies PLCFull Year Results
Pebble Group PLCFull Year Results
Quixant PLCFull Year Results
ScS Group PLCHalf Year Results
SThree PLCTrading Statement
Staffline Group PLCFull Year Results
Tissue Regenix Group PLCFull Year Results
Trustpilot Group PLCFull Year Results
YouGov PLCHalf Year Results
Zotefoams PLCFull Year Results
Wednesday 22 March 
Anpario PLCFull Year Results
Atalaya Mining PLCFull Year Results
BioPharma Credit PLCFull Year Results
Blackbird PLCFull Year Results
Bloomsbury Publishing PLCTrading Statement
Essentra PLCFull Year Results
Fevertree Drinks PLCFull Year Results
Genel Energy PLCFull Year Results
Gresham House PLCFull Year Results
Hostelworld Group PLCFull Year Results
Judges Scientific PLCFull Year Results
Kenmare Resources PLCFull Year Results
LSL Property Services PLCFull Year Results
Mpac Group PLCFull Year Results
NAHL Group PLCFull Year Results
Pendragon PLCFull Year Results
Pharos Energy PLCFull Year Results
Sareum Holdings PLCHalf Year Results
Ten Entertainment Group PLCFull Year Results
Tribal Group PLCFull Year Results
Vistry Group PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
6 Mar 2023 16:16

Sareum looks at options as GSK division returns cancer drug candidate

(Sharecast News) - Biotechnology developer Sareum announced on Monday that GSK subsidiary Sierra Oncology has returned clinical study reports and associated documents related to 'SRA737' to Sareum's co-development partner, the CRT Pioneer Fund.

Read more
6 Mar 2023 11:19

Sareum says GSK's Sierra returns clinical study reports to CRT Pioneer

(Alliance News) - Sareum Holdings PLC on Monday said that GSK PLC subsidiary Sierra Oncology Inc has completed the return of the clinical study reports relating to SRA737 to Sarerum's co-development partner CRT Pioneer Fund LP.

Read more
16 Dec 2022 21:53

TRADING UPDATES: Dev Clever to cancel shares; Tintra raises funds

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
16 Dec 2022 16:55

Sareum confident despite recent setbacks

(Sharecast News) - Autoimmune and cancer-focussed biotechnology company Sareum said in an update on Friday that it remained "confident" despite some recent setbacks.

Read more
16 Dec 2022 10:44

AIM WINNERS & LOSERS: Time Finance jumps on strong first-half results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
9 Dec 2022 15:43

UK shareholder meetings calendar - next 7 days

Monday 12 December 
Devolver Digital IncSGM re 2022 Long-Term Incentive Plan approval
Marwyn Value Investors LtdAGM
Osirium Technologies PLCGM re placing agreement with Allenby Capital
PCF Group PLCGM re proposed cancellation of trading on AIM
Tuesday 13 December 
Amedeo Air Four Plus LtdAGM
Avation PLCAGM
Blancco Technology Group PLCAGM
JD Sports Fashion PLCGM re remuneration policy
Macau Property Opportunities Fund LtdAGM
Softcat PLCAGM
Spectris PLCGM re remuneration policy
Wednesday 14 December 
Fidelity Special Values PLCAGM
Kistos PLCGM re new non-operational entity
Parsley Box Group PLCGM re proposal to become a private limited company
TP Group PLCGM re cash acquisition
Volution Group PLCAGM
Westpac Banking CorpAGM
Thursday 15 December 
Aeorema Communications PLCAGM
Argos Resources LtdAGM
Baillie Gifford Japan Trust PLCAGM
Capricorn Energy PLCGM re proposed share premium account cancellation
Chelverton Growth Trust PLCAGM
CQS Natural Resources Growth & Income PLCAGM
DX Group PLCAGM
DXS International PLCAGM
Glenveagh Properties PLCEGM
Secured Income Fund PLCGM re proposed reduction of capital
Schroder Income Growth Fund PLCAGM
Friday 16 December 
Bellway PLCAGM
Inchcape PLCGM re Derco acquisition
JPMorgan Global Growth & Income PLCGM re proposed combination with JPMorgan Elect PLC
National Australia Bank LtdAGM
Sareum Holdings PLCAGM
Thor Explorations LtdAGM
UP Global Sourcing Holdings PLCAGM
  
Copyright 2022 Alliance News Ltd. All Rights Reserved.

Read more
21 Nov 2022 12:44

IN BRIEF: Sareum salutes publication of SRA737 combination trial data

Sareum Holdings PLC - Cambridge, England-based biotechnology company focused on developing kinase inhibitors for autoimmune disease & cancer - Says it is pleased by the publication of data from the Phase 1/2 trial of SRA737 as a combination treatment for advanced cancers in the medical journal, Clinical Cancer Research.

Read more
24 Oct 2022 10:28

IN BRIEF: Sareum widens annual loss; considers future of SRA737

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - In the year ended June 30, pretax loss widens to GBP2.6 million from GBP1.7 million a year before. No revenue is recorded in either year, but in the previous year it brought in GBP171,000 in other operating income, with none recorded for financial 2022. Says it will discuss the future of SRA737 with partner Cancer Research Technology Pioneer Fund. Earlier this month, GSK PLC subsidiary Sierra Oncology Inc said it intends to return the rights for the SRA737 cancer treatment to CPF.

Read more
12 Oct 2022 10:47

Sareum plunges as GSK subsidiary Sierra returns rights for SRA737

(Alliance News) - Sareum Holdings PLC on Wednesday after Sierra Oncology Inc, a subsidiary of GSK PLC, said it intends to return the rights for SRA737 to the CRT Pioneer Fund LP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.